/Companies

RadioNano Therapeutics㈱

Kyoto, JP · 4 known investors

Find your way into RadioNano Therapeutics㈱

Sign up to see every warm intro you have to RadioNano Therapeutics㈱

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the RadioNano Therapeutics㈱ team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

RadioNano Therapeutics develops boron neutron capture therapy (BNCT), an advanced radiotherapy targeting cancer cells. The company is commercializing RN-501, a nanoparticle-enhanced therapeutic drug aimed at improving treatment safety and efficacy for cancer patients.

Founders & leadership

MCMasatoshi Chiba
Masatoshi ChibaCEOMasatoshi Chiba spent 36 years at Mitsubishi Chemical Group in various pharmaceutical roles including production, drug development, supply chain, research, and business development, before co-founding RadioNano Therapeutics in 2024 to commercialize a boron neutron capture therapy treatment.
HK
Hiroshi KawaiCBO/COO

Investors · 4

Frequently asked questions

What does RadioNano Therapeutics㈱ do?
RadioNano Therapeutics develops boron neutron capture therapy (BNCT), an advanced radiotherapy targeting cancer cells. The company is commercializing RN-501, a nanoparticle-enhanced therapeutic drug aimed at improving treatment safety and efficacy for cancer patients.
Who are RadioNano Therapeutics㈱'s investors?
RadioNano Therapeutics㈱'s investors include Kyoto University Innovation Capital, Japan Science and Technology Agency, Mitsubishi UFJ Capital, DBJ Capital.
Where is RadioNano Therapeutics㈱ headquartered?
RadioNano Therapeutics㈱ is headquartered in Kyoto, JP.